Clinical trials: Blood Plasma Therapy
Waldenstrom Macroglobulinemia
Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia
Current therapies for Recurrent or Refractory Waldenstrom's Macroglobulinemia provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the treatment…
- Trial name
- NCT00003512
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Sponsor
- Burzynski Research Institute
Multiple Myeloma and Plasma Cell Neoplasm
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00004903
- Testing
- filgrastim, recombinant interferon alfa, cisplatin
- Where
- 2 sites in United States
- Sponsor
- Robert H. Lurie Cancer Center
Age Related Macular Degeneration
Treatment of AMD With Rheohemapheresis /RHF/
In this research rheohemapheresis will be used for the treatment of patients with high-risk dry form of age-related macular degeneration.
- Trial name
- TARHF (NCT01943396)
- Testing
- rheohemapheresis
- Where
- Czechia
- Volunteers
- 36 people
- Sponsor
- University Hospital Hradec Kralove
Blood Coagulation Disorders, Hemophilia A
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
The study will assess the pharmacokinetics (part A) safety, tolerability, and efficacy of prophylaxis treatment (2 to 3 times a week) (part B) with BAY81-8973 over a one year period (split into two six month treatment periods).
- Trial name
- Leopold I (NCT01029340)
- Testing
- Recombinant Factor VIII (BAY81-8973), Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 60 sites in United States, Argentina and 20 more
- Volunteers
- 74 people
- Sponsor
- Bayer
Relapsed/Refractory Multiple Myeloma(MM)
CAR-T Cells Therapy in Relapsed/Refractory Multiple Myeloma
Multiple myeloma（MM） is one of the most common malignant diseases in the blood system.There is still no cure for the disease which only control the development of the disease in various ways.Chimeric Antigen Receptor-transduced T…
- Trial name
- MM (NCT03473496)
- Testing
- CART therapy in Relapsed/Refractory multiple myeloma
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Zhujiang Hospital
Waldenstrom Macroglobulinemia
Zanubrutinib Plus BR in Newly Diagnosed Symptomatic WM
This study aims to evaluate the long-term efficacy of BTK inhibitor Zanubrutinib combined bendamustine and rituximab (ZBR) for time-limited treatment of Waldenstrom macroglobulinemia, The combination therapy is expected to…
- Trial name
- ZBR (NCT05914662)
- Testing
- Zanubrutinib, Bendamustine and Rituximab
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Myeloma, Leukemia
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig)
This study is being conducted to find out how safe and effective different strategies of infection prevention are in comparison to each other, for preventing infection in patients with blood cancers.
- Conditions
- Myeloma, Leukemia, Non Hodgkin's Lymphoma
- Trial name
- NCT07202091
- Testing
- Trimethoprim Sulfamethoxazole, Amoxycillin/clavulanic acid, Immune Globulin Intravenous
- Where
- 3 sites in Australia
- Volunteers
- 900 people
- Sponsor
- Monash University
Multiple Myeloma
Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2
This study is being done to find out if the combination of VelcadeTM with melphalan and dexamethasone (VMD) will be as effective, or even more effective as it is in combination with thalidomide and dexamethasone (VTD).
- Trial name
- NCT00573391
- Testing
- Velcade, Thalidomide, and Dexamethasone, Velcade, Melphalan, and Dexamethasone
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- University of Arkansas
Lymphoma, Breast Neoplasms
Chemotherapy Related Anemia in Patients With Non-Myeloid Malignancies
Chemotherapy can often cause anemia in patients with cancer. Anemia is a low number of red blood cells. The symptoms of anemia may include fatigue, dizziness, headache, chest pain, and shortness of breath.
- Conditions
- Lymphoma, Breast Neoplasms, Lung Neoplasms, Multiple Myeloma
- Trial name
- NCT00036023
- Testing
- darbepoetin alfa
- Sponsor
- Amgen
Plasma Cell Myeloma, Transplant-Related Carcinoma
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies the safety of alternating ixazomib citrate and lenalidomide as treatment to help keep cancer from coming back after stem cell transplant (maintenance therapy) in treating patients with multiple…
- Trial name
- NCT02619682
- Testing
- Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
A Study of Belantamab Mafodotin to Investigate Safety, Tolerability, Pharmacokinetics, Immunogenicity and Clinical Activity in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
Multiple myeloma (MM) is a neoplastic plasma cell disorder that is characterized by osteolytic bone lesions, anemia, hypercalcemia and renal failure.
- Trial name
- NCT04177823
- Testing
- Belantamab mafodotin
- Where
- China
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
HIV Infections
A Study of the Safety and Effectiveness of Hydroxyurea in Patients on Potent Antiretroviral Therapy and Who Have Less Than 200 Copies/ml of HIV RNA in Their Blood
This study compares the safety and effectiveness of continuing your current anti-HIV medications to that of adding or switching some of your anti-HIV medications.
- Trial name
- NCT00000916
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Hydroxyurea
- Where
- 34 sites in United States
- Volunteers
- 399 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study)
An effective, widely available, and safe treatment that can decrease the duration, severity and fatality of COVID-19 is urgently needed.
- Trial name
- CoV-Early (NCT04589949)
- Testing
- ConvP, FFP
- Where
- 11 sites in Netherlands
- Volunteers
- 420 people
- Sponsor
- Erasmus Medical Center
Leukemia, Lymphoma
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
RATIONALE: Valproic acid may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It may also help cancer cells become more like normal cells, and grow and spread more slowly.
- Trial name
- NCT01016990
- Testing
- valproic acid, western blotting, laboratory biomarker analysis
- Where
- Puerto Rico
- Volunteers
- 52 people
- Sponsor
- Auxilio Mutuo Cancer Center
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Study of Immune Response Modifier in the Treatment of Hematologic Malignancies
The purpose of this study is to evaluate the anti-tumor activity of 852A when used to treat certain hematologic malignancies not responding to standard treatment.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
- Trial name
- NCT00276159
- Testing
- 852A
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Onychomycosis Due to Trichophyton Rubrum, Onychomycosis Due to Trichophyton Mentagrophytes
Early Feasibility Study to Evaluate the Efficacy and Safety of the RenewalNail™ Plasma Treatment System in Patients With Mild to Moderate Onychomycosis (Fungal Nail)
Early feasibility study to determine if a three-treatment protocol with the RenewalNail™ plasma treatment system over a week will result in mycological cure and/or clear nail growth on the treated hallux toe.
- Trial name
- NCT03072550
- Testing
- RenewalNail™ Plasma Treatment System
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- DeviceFarm, Inc.
Newly Diagnosed Multiple Myeloma
Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients
This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have…
- Trial name
- NCT03733691
- Testing
- Ixazomib, Lenalidomide
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Oncotherapeutics
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
HIV Infections
BASIC: Boosted Atazanavir or Saquinavir Induced Lipid Changes
The purpose of this study is to assess differences in changes in plasma lipids between patients on saquinavir/ritonavir or atazanavir/ritonavir in combination with tenofovir disoproxil fumarate and emtricitabine as a first-line…
- Trial name
- NCT00389402
- Testing
- saquinavir/ritonavir, atazanavir/ritonavir
- Where
- Netherlands
- Volunteers
- 120 people
- Sponsor
- International Antiviral Therapy Evaluation Center
Multiple Myeloma
Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM
The purpose of this study is to compare the safety and efficacy of Lenalidomide versus Placebo maintenance following melphalan, prednisone and velcade induction therapy in newly diagnosed multiple myeloma.
- Trial name
- ARUMM (NCT02112175)
- Testing
- Lenalidomide
- Where
- 73 sites in Belgium, France and 3 more
- Volunteers
- 46 people
- Sponsor
- Celgene